The company has a group of cooperation teams engaged in the lab tube labels industry for many years, with dedication, innovation spirit and service awareness, and has established a sound quality control and management system to ensure product quality.
It’s become an all-too-common refrain — COVID-19, unprecedented demand and supply chain constraints are limiting providers’ ability to acquire the essential products they need for diagnosis and treatment.
Now, along with critical supplies such as certain PPE and IV fluids, blood specimen collection tubes have joined the FDA’s list of medical device shortages. The first signs of trouble occurred in June 2021, when sodium citrate (light blue top) tubes were first identified as a shortage area. The problem has since snowballed, and the FDA’s list was amended in January of this year to include all blood collection tubes.
While suppliers are working to mitigate the shortages through protective allocation strategies and focusing production on tubes with the highest demand, those actions alone won’t immediately solve the problem. Providers must also consider ways to conserve allocated supplies by approaching blood collection in a more strategic — and flexible — way.
Conservation recommendations
In response to provider outreach based on supply needs, we have pinpointed some of the most effective ways to mitigate blood collection tube shortages:
The importance of communication
Clearly communicating mitigation strategies is always of critical importance — something one large health system based in the southeastern U.S. discovered while navigating this very shortage during spring 2021. They found that tailoring communications to their many different teams enabled them to successfully build and maintain their tube-management strategy. Their communications included:
Not only did this communication strategy allow them to shape effective messaging to targeted audiences, but their data collection strategy also helped them identify where extra tube rates were occurring and intervene to improve overall competence.
Outlook
There’s no real guarantee yet as to when blood collection tubes will rebound to their full level of availability. The ever-fluctuating supply chain means it’s critical to always keep conservation strategies top of mind to ensure supply is available for necessary testing a quality patient care.
Jake Hagen joined Vizient in 2015 as part of a two-year rotational program supporting contracting and analytics. Over the past four years, he has been part of the sourcing team, and in his current role as a portfolio executive on the medical, surgical, laboratory distribution team, he has responsibilities over laboratory national contracts and blood bank, blood gas, hematology, phlebotomy and point of care glucose. He earned a bachelor’s degree in business administration from the University of North Texas.
If you have any questions on lab tube labels. We will give the professional answers to your questions.